Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232581 | 0.79 | PRCP (0.32) | PRCP | |
| SCHEMBL230172 | 0.75 | PRCP (0.32) | PRCP | |
| SCHEMBL232814 | 0.72 | GRIN1 (0.31) | — | |
| SCHEMBL13280965 | 0.64 | — | — | |
| SCHEMBL3711365 | 0.62 | CHRM2 (0.41) | CHRM5CHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL9370080 | 0.58 | GRIN1 (0.49) | PRCP | |
| SCHEMBL9802807 | 0.58 | SLC6A2 (0.33) | — | |
| SCHEMBL929054 | 0.58 | GRIN1 (0.49) | PRCP | |
| SCHEMBL1397537 | 0.57 | GRIN1 (0.41) | PRCP | |
| SCHEMBL1758838 | 0.55 | PBRM1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319397-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-12-29 | — | — | US | claimed |
| WO-2010086280-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-08-05 | — | — | WO | claimed |
| US-20110319397-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-20110319397-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| WO-2010086280-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086280-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319397-A1 | NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA10, CHRNA7, CHRNA3 | PRCP 4513/4885CHRM5 29/4885CHRM3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.